Compare DRD & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | AMRX |
|---|---|---|
| Founded | 1895 | 2002 |
| Country | South Africa | United States |
| Employees | 3410 | 8500 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | N/A | 2018 |
| Metric | DRD | AMRX |
|---|---|---|
| Price | $26.02 | $11.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $32.63 | $14.75 |
| AVG Volume (30 Days) | 310.5K | ★ 1.9M |
| Earning Date | 08-19-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | $34.35 | $6.40 |
| Revenue Next Year | $24.62 | $6.54 |
| P/E Ratio | ★ $15.32 | $56.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.08 | $6.69 |
| 52 Week High | $39.37 | $15.42 |
| Indicator | DRD | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.93 | 28.89 |
| Support Level | $23.26 | $11.62 |
| Resistance Level | $30.91 | $12.12 |
| Average True Range (ATR) | 1.22 | 0.44 |
| MACD | -0.91 | -0.13 |
| Stochastic Oscillator | 3.35 | 3.24 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.